BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
Bon Natural Life (Nasdaq: BON) has announced a significant breakthrough in weight management research through its AI-powered drug R&D platform. The company has identified natural polyphenolic compounds from tea products that show promising weight management potential, outperforming current mainstream medications in preliminary tests.
The discovery comes amid a growing global weight management market, which reached $423.27 billion in 2024 and is projected to grow at a 9.5% CAGR to $601.26 billion by 2029. Initial animal studies demonstrated significant weight reduction with no obvious adverse effects. BON has assembled a dedicated team to advance research, including mechanism studies, structural optimization, expanded trials, and clinical trial preparations.
Bon Natural Life (Nasdaq: BON) ha annunciato un importante progresso nella ricerca sulla gestione del peso grazie alla sua piattaforma di R&S farmacologica potenziata dall'IA. L'azienda ha individuato composti polifenolici naturali presenti nei prodotti a base di tè che mostrano un promettente potenziale per la gestione del peso, superando nei test preliminari i farmaci attualmente più diffusi.
La scoperta arriva in un mercato globale della gestione del peso in crescita, che ha raggiunto 423,27 miliardi di dollari nel 2024 e si prevede cresca a un CAGR del 9,5% fino a 601,26 miliardi di dollari entro il 2029. I primi studi su animali hanno evidenziato una riduzione significativa del peso senza effetti avversi evidenti. BON ha costituito un team dedicato per portare avanti la ricerca, incluse indagini sui meccanismi, ottimizzazione strutturale, ampliamento delle sperimentazioni e preparazione alle prove cliniche.
Bon Natural Life (Nasdaq: BON) ha anunciado un avance significativo en la investigación del control de peso gracias a su plataforma de I+D de fármacos impulsada por IA. La compañía ha identificado compuestos polifenólicos naturales en productos de té que muestran un prometedor potencial para el control del peso, superando en pruebas preliminares a los medicamentos convencionales.
El hallazgo se produce en un mercado global de gestión del peso en crecimiento, que alcanzó los $423.27 mil millones en 2024 y se proyecta que crezca a un 9.5% de CAGR hasta $601.26 mil millones para 2029. Los estudios iniciales en animales demostraron una reducción de peso significativa sin efectos adversos evidentes. BON ha formado un equipo dedicado para avanzar en la investigación, incluyendo estudios de mecanismo, optimización estructural, ensayos ampliados y preparativos para ensayos clínicos.
Bon Natural Life (Nasdaq: BON)는 AI 기반 약물 연구개발 플랫폼을 통해 체중 관리 연구에서 중요한 성과를 발표했습니다. 회사는 차(tea) 제품에서 천연 폴리페놀 화합물을 확인했으며, 예비 실험에서 현재 주류 약물보다 우수한 체중 관리 잠재력을 보였습니다.
이번 발견은 전 세계 체중 관리 시장이 성장하는 가운데 이루어졌으며, 해당 시장은 2024년 4,232.7억 달러에 달했고 2029년까지 연평균 9.5% 성장하여 6,012.6억 달러가 될 것으로 전망됩니다. 초기 동물 실험에서는 뚜렷한 부작용 없이 유의미한 체중 감소가 관찰되었습니다. BON은 기전 연구, 구조 최적화, 시험 확대 및 임상시험 준비 등을 진행할 전담팀을 구성했습니다.
Bon Natural Life (Nasdaq: BON) a annoncé une avancée importante dans la recherche sur la gestion du poids grâce à sa plateforme R&D de médicaments alimentée par l'IA. La société a identifié des composés polyphénoliques naturels présents dans des produits à base de thé qui montrent un potentiel prometteur pour la gestion du poids, surpassant les médicaments actuellement répandus lors de tests préliminaires.
Cette découverte intervient dans un marché mondial de la gestion du poids en expansion, qui a atteint 423,27 milliards de dollars en 2024 et devrait croître à un TCAC de 9,5 % pour atteindre 601,26 milliards de dollars d'ici 2029. Les premières études animales ont montré une réduction de poids significative sans effets indésirables évidents. BON a constitué une équipe dédiée pour faire progresser la recherche, incluant des études de mécanisme, l'optimisation structurelle, l'élargissement des essais et les préparatifs des essais cliniques.
Bon Natural Life (Nasdaq: BON) hat einen bedeutenden Durchbruch in der Forschung zur Gewichtskontrolle bekanntgegeben – dank seiner KI-gestützten Plattform für die Wirkstoffforschung. Das Unternehmen hat natürliche polyphenolische Verbindungen aus Teeprodukten identifiziert, die vielversprechendes Potenzial für die Gewichtskontrolle zeigen und in ersten Tests besser abschnitten als derzeit gängige Medikamente.
Die Entdeckung erfolgt vor dem Hintergrund eines wachsenden globalen Marktes für Gewichtsmanagement, der 2024 423,27 Milliarden USD erreichte und voraussichtlich mit einem CAGR von 9,5% auf 601,26 Milliarden USD bis 2029 anwachsen wird. Erste Tierversuche zeigten eine signifikante Gewichtsreduktion ohne erkennbare Nebenwirkungen. BON hat ein dediziertes Team zusammengestellt, um die Forschung voranzutreiben, darunter Wirkmechanismus-Studien, strukturelle Optimierung, erweiterte Versuchsreihen und die Vorbereitung klinischer Studien.
- None.
- Early-stage research requiring extensive further testing and clinical trials
- No guaranteed timeline for product commercialization
- Potential regulatory hurdles in drug development process
Insights
BON's AI platform identifies promising weight-management compounds from tea, potentially positioning the company to compete in the $423B market with superior efficacy.
BON Natural Life has made a significant breakthrough in the weight management space, identifying natural polyphenolic compounds from tea using their AI-powered drug R&D platform. What stands out is that these compounds reportedly outperform current mainstream weight-management drugs in preliminary efficacy indicators—a remarkable claim in a field dominated by established medications like Wegovy and Ozempic.
The preliminary animal studies showed significant weight reduction with no obvious adverse effects at specific doses—addressing both efficacy and safety concerns that are paramount in this therapeutic area. This dual benefit could provide a competitive advantage if confirmed in human trials.
The company's AI platform has demonstrated value by substantially shortening the component screening cycle in drug R&D. This technological advantage allows BON to efficiently identify active molecules from natural sources, potentially creating a repeatable process for future drug discoveries beyond weight management.
The market opportunity is substantial, with the global weight management product market valued at
BON's next steps include researching the compounds' mechanisms of action, structural optimization, expanded animal trials, and preparation for clinical trials—all critical milestones in the drug development pathway. The company has assembled a dedicated team for these efforts, indicating organizational commitment to advancing this discovery.
With a worsening global obesity crisis, the weight-managing product market is experiencing robust growth. Data shows that the global weight-managing product market reached
BON's AI platform integrates massive datasets of natural compounds and biomedical knowledge, leveraging advanced algorithms and innovative models. Its high-efficiency data analysis and screening capabilities have significantly shortened the component screening cycle traditionally associated with drug R&D, enabling the successful identification of these compounds with weight-loss potential. Preliminary animal studies showed significant weight reduction at specific compound doses, with no obvious adverse effects observed. Currently, the Company has established a dedicated team to advance follow-up work, including research into the compounds' mechanisms of action, structural optimization, expanded animal trials, and preparation for clinical trials.
BON believes that the weight-managing product market represents a large-scale therapeutic area with substantial growth potential. If the Company successfully launches this new drug, it is well-positioned to capture a significant share of the global weight management therapeutics market - a development that would fundamentally and revolutionarily enhance the Company's investment value while delivering substantial returns to shareholders.
Meanwhile, this R&D breakthrough has enabled the Company to efficiently and accurately identify weight-managing active molecules from natural tea-derived products. It also provides preliminary validation of the feasibility of BON's AI-based new drug R&D platform, helping the Company establish a highly efficient, new R&D model. This will lay a solid foundation for the Company's AI-driven R&D business focused on natural compound-based new drugs, accelerate the development of its AI-powered innovative drug research initiatives, and continue to create greater value for shareholders.
References：
1. https://www.thebusinessresearchcompany.com/report/weight-management-global-market-report
About Bon Natural Life Limited ("BON")
BON is a
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/bon-announces-identification-of-promising-weight-managing-compounds-from-tea-via-ai-powered-new-drug-rd-platform-302543536.html
SOURCE Bon Natural Life Limited
FAQ
What breakthrough did Bon Natural Life (BON) announce in weight management research?
How big is the weight management market that BON is targeting?
What were the results of BON's preliminary animal studies?
What are the next steps in BON's weight management drug development?
How does BON's AI-powered drug R&D platform work?
